Compare SOPA & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOPA | SHPH |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2M | 5.2M |
| IPO Year | 2021 | 2022 |
| Metric | SOPA | SHPH |
|---|---|---|
| Price | $0.08 | $0.45 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $22.50 | N/A |
| AVG Volume (30 Days) | ★ 2.3M | 228.6K |
| Earning Date | 05-19-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,171,635.00 | N/A |
| Revenue This Year | $2.43 | N/A |
| Revenue Next Year | $71.20 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 45.00 | N/A |
| 52 Week Low | $0.07 | $0.12 |
| 52 Week High | $6.28 | $5.59 |
| Indicator | SOPA | SHPH |
|---|---|---|
| Relative Strength Index (RSI) | 19.75 | 28.43 |
| Support Level | N/A | N/A |
| Resistance Level | $0.66 | $0.64 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 2.06 | 18.93 |
Society Pass Inc is building an ecosystem of platforms and technology-enabled companies that synergistically work together to transform how consumers and merchants interact with one another in Southeast Asia and South Asia. Through the acquisition of companies and partnerships with entrepreneurs, the company meets the growing demand for services in sectors such as lifestyle, beauty, travel, and food and beverage. The company currently operates in Six reportable operating segments: Online Grocery and Food deliveries, Digital marketing, Online ticketing and reservation, Telecommunications Reseller, e-commerce, and Corporate. The company generates the majority of its revenue from the Digital marketing segment.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.